Erratum: Sulfonamide cross-reactivity: Fact or fiction? (Annals of Pharmacotherapy (January 11, 2005) 39 (290-300) DOI: 10.1345/aph.1E350);Sulfonamide cross-reactivity: Fact or fiction?

Annals of Pharmacotherapy

Volumn 39, Issue 2, 2005, Pages 290-301

  Johnson, Kelly K ^a,b   Green, David L ^c,d   Rife, Jason P ^e   Limon, Lynn ^a,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^c Virginia Cmw Univ Medical Center   (United States)

^d Sherman Hospital   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cross reaction; Hypersensitivity; Sulfonamide

Indexed keywords

ACETAZOLAMIDE; ACETOHEXAMIDE; BUMETANIDE; CARBONATE DEHYDRATASE INHIBITOR; CHLOROTHIAZIDE; CHLORPROPAMIDE; CHLORTALIDONE; CYCLOOXYGENASE 2 INHIBITOR; DORZOLAMIDE; FUROSEMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METHAZOLAMIDE; METHYCLOTHIAZIDE; SEROTONIN 1D AGONIST; SEROTONIN 3 ANTAGONIST; SULFADIAZINE; SULFAMETHOXAZOLE; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TOLAZAMIDE; TOLBUTAMIDE; TORASEMIDE; UNINDEXED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONTACT DERMATITIS; CROSS REACTION; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DYSESTHESIA; ECZEMA; EDEMA; EYE DISEASE; FEVER; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOKALEMIA; HYPOTENSION; LEUKOCYTOCLASTIC VASCULITIS; LIVER TOXICITY; MEDLINE; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; REVIEW; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VASCULITIS; VERTIGO;

EID: 12844283281     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E350c     Document Type: Erratum

References (88)

1. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim anti-microbials: clinical syndromes and pathogenesis. Advers Drug React Toxicol Rev 1996;15:9-50.
2. Choquet-Kastylevsky G, Vial T, Descotes J. Allergic adverse reactions to sulfonamides. Curr Allergy Asthma Rep 2002;2:16-25.
3. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Saf 2001;24:239-47.
4. Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001;94:817-24.
5. Strom BL, Schinnar R, Apter A, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349:1628-35. DOI 10.1056/nejm.oa022963
6. Kuritzky L. Compounds that pose a risk for the "sulfur"- sensitive patient. Family Pract Forum 1995;10:761-766.
7. Dwenger CS. 'Sulpha' hypersensitivity (letter). Anaesthesia 2000;55:200-1. DOI 10.1046/j.1365-2044.2000.e1313.x
8. Duncan C. Sulfonamide cross allergenicity - answers to common questions. Hosp Pharm 1989;24:666-8.
9. Reilly TP, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous reactions. Curr Op All Clin Immunol 2002;2:307-15.
10. Harle DG, Baldo BA, Wells JV. Drugs as allergens: detection and combining site specificites of IgE antibodies to sulfamethoxazole. Mol Immunol 1988;25:1347-54. DOI 10.1016/0161-59(88)90050-8
11. Lanctot KL, Ghajar BM, Shear NH, Naranjo CA. Improving the diagnosis of hypersensitivity reactions associated with sulfonamides. J Clin Pharmacol 1994;34:1228-33.
12. Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy 1999;54(suppl 58):28-32.
13. Package insert. Acetazolamide. Hawthorne, NY: Taro Pharmaceuticals, February 1997.
14. Package insert. Methazolamide. Wayne, NJ: Lederle Laboratories, March 1996.
15. Package insert. Trusopt (dorzolamide). Whitehouse Station, NJ: Merck and Company, October 2001.
16. Package insert. Azopt (brinzolamide). Fort Worth, TX: Alcon Laboratories, April 2002.
17. Package insert. Tolbutamide. Kalamazoo, MI: Upjohn, June 1994.
18. Package insert. Chlorpropamide. Morgantown, WV: Mylan Pharmaceuticals, May 1998.
19. Package insert. Acetohexamide. Pomona, NY: Barr Laboratories, September 2000.
20. Package insert. Tolazamide. Miami, FL: Ivax Pharmaceuticals, November 2001.
21. Package insert. Amaryl (glimepiride). Bridgewater, NC: Aventis Pharmaceuticals, March 2002.
22. Package insert. Glucotrol (glipizide). New York: Roerig Pharmaceuticals, August 2003.
23. Package insert. Glyburide. Peapack, NJ: Greenstone Ltd., October 2000.
24. Package insert. Furosemide. Miami: Ivax Pharmaceuticals, October 2001.
25. Package insert. Demadex (torsemide). Nutley, NJ: Roche Laboratories, April 2001.
26. Package insert. Bumex (bumetanide). Nutley, NJ: Roche Laboratories, March 2003.
27. Package insert. Hydrochlorothiazide. Miami: Ivax Pharmaceuticals, January 2002.
28. Package insert. Methyclothiazide. Chicago: Abbott Laboratories, April 1998.
29. Package insert. Chlorthalidone. Morgantown, WV: Mylan Pharmaceuticals, October 2002.
30. Package insert. Indapamide. Morgantown, WV: Mylan Pharmaceuticals, January 2002.
31. Package insert. Zaroxolyn (metolozone). New York: Celltech Pharmaceuticals, May 2001.
32. Package insert. Hyperstat (diazoxide). Kenilworth, NJ: Schering Corporation, August 2003.
33. Package insert. Imitrex (sumatriptan). Research Triangle Park, NC: GlaxoSmithKline, August 2003.
34. Package insert. Amerge (naratriptan). Research Triangle Park, NC: GlaxoSmithKline, August 2003.
35. Package insert. Celebrex (celecoxib). New York: GD Searle LLC, August 2002.
36. Package insert. Vioxx (rofecoxib). Whitehouse Station, NJ: Merck & Company, September 2004.
37. Package insert. Bextra (valdecoxib). New York: GD Searle LLC, August 2003.
38. Package insert. Agenerase (amprenavir). Research Triangle Park, NC: GlaxoSmithKline, February 2004.
39. Package insert. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, February 2004.
40. Package insert. Zonegran (zonisamide). San Diego: Elan Biopharmaceuticals, June 2002.
41. Package insert. Corvert (ibutilide). Kalamazoo, MI: Pharmacia & Upjohn Company, October 2002.
42. Package insert. Betapace (sotalol). Montville, NJ: Berlex Laboratories, October 2001.
43. Package insert. Topamax (topiramate). Raritan NJ: Ortho McNeil Pharmaceuticals, August 2004.
44. Package insert. Dapsone. Princeton, NJ: Jacobus Pharmaceutical Company, June 1997.
45. Package insert. Probenecid. Morgantown, WV: Mylan Pharmaceuticals, June 1998.
46. Gallerani M, Manzoli N, Fellin R, Simonato M, Orzincolo C. Anaphylactic shock and acute pulmonary edema after single oral dose of acetazolamide (letter). Am J Emerg Med 2002;20:371-2. DOI 10.1053/ajem.2002.33774
47. Peralta J, Abelairas J, Fernandez-Guardiola J. Anaphylactic shock and death after oral intake of acetazolamide (letter). Am J Ophthalmol 1992;114:367.
48. Kristinsson A. Fatal reaction to acetazolamide. Br J Ophthalmol 1967;51:348-9.
49. Mosely V, Baroody NB. Some observations on the use of acetazolamide ("Diamox") as an oral diuretic in various edematous states and in uremia with hyperkalemia. Am Pract Dig Treat 1955;6:558-66.
50. Stock JG. Sulfonamide hypersensitivity and acetazolamide (letter). Arch Ophthalmol 1990;108:34-5.
51. Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide (letter). Br J Ophthalmol 1998;82:588.
52. Thirumala Krishna M. Anaphylaxis. In: Thirumala Krishna M. Marroleon G, Holgate T, eds. Essentials of allergy. London: Blackwell Science, 2003:77-84.
53. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol 1991;88:784-92.
54. Carrington DM, Earl HS, Sullivan TJ. Studies of human IgE to a sulfonamide determinant. J Allergy Clin Immunol 1987;79:442-7.
55. Ravid M, Rubinstein E, Cabili S. Anaphylactic reaction to chlorpropamide (letter). BMJ 1971;3:162.
56. Fisher AA. Systemic contact dermatitis from Orinase and Diabinese in diabetics with para-amino hypersensitivity. Cutis 1982;29:551, 556, 561, 565.
57. Angelini G, Meneghini CL. Oral tests in contact allergy to para-amino compounds. Contact Dermatitis 1981;7:311-4.
58. Bukhalo M, Zeitouni NC, Cheney RT. Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. Cutis 2003;71:235-8.
59. Lin RY. Unusual autoimmune manifestations in furosemide associated hypersensitivity angiitis. N Y State J Med 1988;88:439-40.
60. Clarke BF, Campbell IW, Ewing DJ, Beveridge GW, MacDonald MK. Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes 1974;23:739-42.
61. Shenfield GM, Jacka J. Adverse drug reactions (letter). Lancet 2001;357:561.
62. Hansbrough JR, Wedner HJ, Chaplin DD. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol 1987;80:538-41.
63. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999;21:2065-79. DOI 10.1016/80149-2918(00)87238-0
64. Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides (letter). JAMA 1991;265:120-1. DOI 10.1001/jama.265.1.120
65. Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf 2003;26:187-95.
66. Wall GC, Bigner D, Craig S. Ethacrynic acid and the sulfa sensitive patient. Arch Intern Med 2003; 163:116-7. DOI 10.1001/archinte.163.1.116
67. Barrio M, Tornero P, Baeza ML, Moral A, Chivato T, Armentia L, et al. Cross reactivity among the para-amine group in sulfonamide-induced urticaria and fixed drug eruptions (abstract 364). J Allergy Clin Immunol 1991;1:230.
68. Stricker BH, Biriell C. Skin reactions and fever with indapamide (letter). BMJ 1987;295:1313-4.
69. DeBarrio M, Tornero P, Zubeldia JM, Sierra Z, Matheu V, Herrero T. Fixed drug eruptions induced by indapamide. Cross reactivity with sulfonamides. Invest Allergol Clin Immunol 1998;8:253-5.
70. Partanen J, Pohjola-Sintonen S, Makijarvi M, Harma M. Toxic epidermal necrolysis due to indapamide (letter). Arch Dermatol 1993;129:793. DOI 10.1001/archderm.126.6.7936
71. Newman LC, Lay CL, O'Connor KA, Russell M. Lack of cross-reactivity to sumatriptan in patients allergic to sulfonamides: a retrospective chart review (abstract). Headache 1999;5:372.
72. Grob M, Scheidegger P, Wuthrich B. Allergic skin reaction to celecoxib (letter). Dermatology 2000;201:383. DOI 10.1159/000051569
73. Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy 2002;22:637-40. DOI 10.1592/phco.22.8.637. 33200
74. Kaur C, Sarkar R, Kanwar AJ. Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides (letter). Dermatology 2001;203:351. DOI 10.1159/000051790
75. Glasser DL, Burroughs SH. Valdecoxib induced epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003;23:551-3. DOI 10.1592/phco.23.4.551.32118
76. Jimenez-Carrillo R, Nurnberger M. Celecoxib induced acute pancreatitis and hepatitis: a case report. Arch Intern Med 2000;160:553-4. DOI archinte.160.4.553
77. Runzi M, Layer P. Drug associated pancreatitis: facts and fiction. Pancreas 1996;13:100-9.
78. Galan MV, Gordon SC, Silverman AL. Celecoxib induced cholestatic hepatitis (letter). Ann Intern Med 2001;134:254.
79. Alegria P, Lebre L, Chagas C. Celecoxib induced cholestatic hepatotoxicity in a patient with cirrhosis (letter). Ann Intern Med 2002;137:75.
80. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001;77:548-50. DOI 10.1136/pmj.77.910.548
81. Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G. Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002;36:1887-9. DOI 10.1345/aph.1C110
82. Shuster C, Wuthrich B. Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence? (letter) Allergy 2003;58:1072. DOI 10.1034/j.1398-9995.2003.100116.x
83. Data on file. Research Triangle Park, NC: Glaxo Smith Kline, 2004.
84. Shelton MJ, Kuhman L, Wynn H, Hewitt R, Scott J. Risk of amprenavir rash in HIV patients with prior exposure to sulfonamides (abstract 1738). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001.
85. Data on file. San Diego, CA: Elan Pharmaceuticals, 2004.
86. Ritter FJ, Gustafson MC, Karney V, Penovich PE, Moriarty GL, Frost MD, et al. Do allergic reactions to sulfonamide antibiotics predict allergy to zonisamide? (abstract) Epilepsia 2002;43(suppl 7):209.
87. McJilton JS, Ramsey RE, Junco-Valladares J. Sulfa-drug allergies and zonisamide (poster). Presented at: 2001 Annual Meeting of the American Epilepsy Society, Philadelphia, November 30-December 5, 2001.
88. Schneiweiss F. Cross-sensitivity between sulfonamides and furosemide (letter). Clin Pharm 1983;2:510.